BMJ  2003;327:65-66 (12 July), doi:10.1136/bmj.327.7406.65

Editorial

Balancing benefits and harms in health care

We need to get better evidence about harms

The first 150 words of the full text of this article appear below.

Should kids be plastered with sunscreen this summer? Is this likely to be more beneficial than harmful? How would we know? For example, sunscreen use has been associated with overexposure to the sun, perhaps because of overconfidence in its abilities.^{1 2} Might there also be a potential risk of developing contact allergies, skin irritation, and rare but severe adverse effects? People making a decision about whether or not to use sunscreen need reliable evidence on the balance of benefits and harms. The same is true of all healthcare interventions, and unfortunately reliable evidence on harms is often lacking.

Great progress has been made in obtaining reliable evidence on the beneficial effects of interventions, but developments in the identification, interpretation, and reporting of harmful effects is more challenging. Randomised controlled trials are the best way to evaluate small to moderate effects of healthcare interventions, and much of the evidence for benefits from . . . [Full text of this article]

BMJ Knowledge, London WC1H 9JR, (lgcuervo@bmjgroup.com)

Cochrane Collaboration Steering Group, Cochrane Collaboration Secretariat, Oxford OX2 7LG, (mclarke@cochrane.co.uk)

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data

Angela C Webster, Rebecca C Woodroffe, Rod S Taylor, Jeremy R Chapman, and Jonathan C Craig
BMJ 2005 331: 810. [Abstract] [Full Text] [PDF]

Balancing benefits and harms in health care: Observational data on harm should complement systematic reviews of benefit

Jan P Vandenbroucke
BMJ 2003 327: 750. [Extract] [Full Text]

Balancing benefits and harms in health care: Observational data on harm are already included in systematic reviews

Tom Jefferson and Vittorio Demicheli
BMJ 2003 327: 750. [Extract] [Full Text]

This article has been cited by other articles:

• Marinho, V.C.C. (2008). Evidence-based Effectiveness of Topical Fluorides. Adv. Dent. Res. 20: 3-7 [Full text]  
• Armstrong, R., Waters, E., Moore, L., Riggs, E., Cuervo, L. G., Lumbiganon, P., Hawe, P. (2008). Improving the reporting of public health intervention research: advancing TREND and CONSORT. J Public Health (Oxf) 30: 103-109 [Abstract] [Full text]  
• Isacson, D., Johansson, L., Bingefors, K. (2008). Nationwide Survey of Subjectively Reported Adverse Drug Reactions in Sweden. The Annals of Pharmacotherapy 42: 347-353 [Abstract] [Full text]  
• Webster, A. C, Woodroffe, R. C, Taylor, R. S, Chapman, J. R, Craig, J. C (2005). Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 331: 810- [Abstract] [Full text]  
• Woolf, S. H., Chan, E. C.Y., Harris, R., Sheridan, S. L., Braddock, C. H. III, Kaplan, R. M., Krist, A., O'Connor, A. M., Tunis, S. (2005). Promoting Informed Choice: Transforming Health Care To Dispense Knowledge for Decision Making. ANN INTERN MED 143: 293-300 [Abstract] [Full text]  
• Chou, R., Helfand, M. (2005). Challenges in Systematic Reviews That Assess Treatment Harms. ANN INTERN MED 142: 1090-1099 [Abstract] [Full text]  
• GIJSMAN, H. J. (2005). Mania After Transcranial Magnetic Stimulation in PTSD. Am. J. Psychiatry 162: 398-398 [Full text]  
• Ioannidis, J. P.A., Evans, S. J.W., Gotzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., for the CONSORT Group*, (2004). Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement. ANN INTERN MED 141: 781-788 [Abstract] [Full text]  
• Vandenbroucke, J. P (2004). Benefits and harms of drug treatments. BMJ 329: 2-3 [Full text]  
• Pirmohamed, M., Darbyshire, J. (2004). Collecting and sharing information about harms. BMJ 329: 6-7 [Full text]  
• Gijsman, H. J., Cohen, A. F., van Gerven, J. M. A. (2004). Reply to Anderson, Bailey, Pinder. J Psychopharmacol 18: 18-19  
• McPherson, K., Hemminki, E. (2004). Synthesising licensing data to assess drug safety. BMJ 328: 518-520 [Full text]  
• Lewis, S C, Warlow, C P (2004). How to spot bias and other potential problems in randomised controlled trials. J. Neurol. Neurosurg. Psychiatry 75: 181-187 [Full text]  
• Baum, M. (2004). Commentary: False premises, false promises and false positives--the case against mammographic screening for breast cancer. Int J Epidemiol 33: 66-67 [Full text]  
• Vandenbroucke, J. P (2003). Balancing benefits and harms in health care: Observational data on harm should complement systematic reviews of benefit. BMJ 327: 750-750 [Full text]  
• Jefferson, T., Demicheli, V. (2003). Balancing benefits and harms in health care: Observational data on harm are already included in systematic reviews. BMJ 327: 750-750 [Full text]  

Rapid Responses:

Read all Rapid Responses

Observational data on harm should complement systematic reviews of benefit

Jan P Vandenbroucke
bmj.com, 15 Jul 2003 [Full text]

Screening and immunizations

Scott L. Johnston
bmj.com, 15 Jul 2003 [Full text]

Observational Data on Harm is Already Included in Systematic Reviews

Tom Jefferson, et al.
bmj.com, 18 Jul 2003 [Full text]